Chagas disease (CD) is a public health problem that affects approximately 8 million people worldwide[@B1]. Most individuals in the chronic phase of the disease present the indeterminate clinical form, which is characterized by the absence of clinical, radiological, and electrocardiographic manifestations of cardiac or digestive involvement[@B2] ^,^ [@B3]. Approximately 30% of the patients with chronic Chagas disease will develop cardiac and/or digestive symptoms and may require symptomatic pharmacological treatment[@B2] ^,^ [@B3]. Many patients also present comorbidities such as arterial hypertension, diabetes mellitus, and dyslipidemia, which are conditions that demand the use of one or more drugs for treatment[@B4]. However, these drugs may interact and contribute to the occurrence of adverse drug events (ADEs) that might not be related to the therapeutic dose. Therefore, the present study aimed to identify factors that might be associated with ADEs among patients with chronic CD.

This retrospective cohort study consisted of patients with chronic CD from Evandro Chagas National Institute of Infectious Diseases (INI) of Oswaldo Cruz Foundation (Fiocruz). The diagnosis of CD was confirmed by two different serological tests (ELISA and indirect immunofluorescence assay) for all patients that visited our outpatient clinical service between 1986 and 2015. The present study was approved by the Evandro Chagas National Institute of Infectious Disease Review Board (number 09935312.0.0000.5262).

The clinical and sociodemographic variables included in the present study were age, sex, level of education, race, marital status, alcohol consumption, stage of Chagas heart disease (A, B1, B2, C, and D)[@B2], number of drugs per prescription, causality, and severity of ADEs. The algorithm of Naranjo was used to determine the causality of the ADE. This algorithm considers the time compatibility between the start of reaction and drug use, the nature of the event and its pharmacological characteristics, and medical or pharmacological plausibility. The algorithm consists of ten questions, with two choices, positive (\"yes\") or negative (\"no\"). Based on the scores generated by the algorithm, the ADEs were classified as doubtful (score 0), possible (score 1-4), likely (score 5-8), or defined (score ≥ 9)[@B5]. The drugs suspected of causing ADEs were identified. The primary outcome was the presence of clinically relevant ADEs for patients who had their drug prescription changed and presented a causality equal to or greater than 1[@B5] ^,^ [@B6]. The reaction was also described in the leaflet of the suspected drug. ADEs were classified into four categories of intensity: 1) mild, usually transient, requiring no special treatment and not interfering with the volunteer\'s normal daily activities; 2) moderate, reaction that altered the normal activity of the patient, thereby warranting hospital or emergency care services and withdrawal from work; 3) severe, a reaction that directly threatened the patient\'s life, and 4) fatal, a reaction that led to the patient\'s death[@B6] ^,^ [@B7].

Statistical analyses were performed using RStudio (RStudio Team, 2015). Descriptive analysis was expressed as mean (SD). The mixed effects logistic regression was performed using glmer function in the lme4 R package and estimates of the risk ratios were calculated using odds_to_rr function in the sjstats package. Models included a random intercept by patient. Multivariate analysis included age, sex, stages of CD, and number of prescribed drugs that were selected due to their association with the ADEs described in the literature. The significance level was set at 5%.

We analyzed 320 medical notes from 295 patients (mean age, 57.4 years) followed from November 1986 to December 2015 to measure the frequency of ADEs. Stages C and D were grouped together owing to the small number of cases (48 with stage C and 4 with stage D). Of the 102 ADEs, 77 patients had at least one ADE and 25 had more than one ADE ([Table 1](#t1){ref-type="table"}).

TABLE 1:Characteristics of the study population and the association estimates (risk ratio) for adverse drugs events (n=320 medical notes from 295 patients).Variablen (320)%Univariate RRMultivariate RR(95%CI)\*(95%CI)\***Age**Mean(SD)57.4\-\--0.960.96(11.2)(0.94-0.99)(0.94-0.99)**Sex**Men13140.9Reference\-\--Women18959.10.991.23(0.50-1.66)(0.64-1.94)**Schooling**Illiterate4815Reference\-\--Primary21968.41.14\-\--(0.42-2.19)Secondary4714.70.73\-\--(0.15-2.09)Tertiary61.90.57\-\--(0.01-3.06)**Race**White14344.7Reference\-\--Mulatto12739.71.01\-\--(0.48-1.77)Black5015.61.11\-\--(0.40-2.15)**Marital status**Single11134.7Reference\-\--Married18658.11.21\-\--(0.62-1.97)Widowed237.20.29\-\--(0.03-1.56)**Alcohol Consumption**No13366.8Reference\-\--Yes6633.20.98\-\--(0.45-1.76)**Stages of Chagas disease**Indeterminate5115.9ReferenceReferenceA12840.01.431.56(0.45-3.11)(0.49-3.28)B16720.91.872.00(0.57-3.71)(0.61-3.84)B2226.93.363.27(1.08-4.75)(0.96-4.75)C4815.03.113.24(1.24-4.51)(1.30-4.58)D41.2**Number of drugs per prescription**0-192.8Reference\-\--2-410332.21.551.35(0.14-4.01)(0.12-3.88)5-1220865.01.201.01(0.10-3.79)(0.08-3.64)**Causality**Definite4112.8(\< 0.001)\*\*\-\--Probable247.5\-\--Possible3711.6\-\--Doubtful/no event21868.1\-\--**Severity**Mild5918.4(\< 0.001)\*\*\*\-\--Moderate3811.9\-\--Severe51.6\-\--No event21868.1\-\--[^3]

The variables that maintained significant associations with ADEs in the multivariate analysis were age (RR 0.96; 95%CI 0.94-0.99) and the C/D stages of Chagas heart disease (RR 3.24; 95%CI 1.30-4.58) ([Table 1](#t1){ref-type="table"}).

The angiotensin converting enzyme inhibitor (ACE inhibitor) (n = 34; 33.3%) was the most frequent cause of ADEs. This drug was followed by amiodarone (n = 13; 12.7%), acetylsalicylic acid (ASA) (n = 9; 8.8%), hydrochlorothiazide (7; 6.9%), spironolactone (n = 6; 5.9%), and warfarin (n = 5; 4.9%) ([Table 2](#t2){ref-type="table"}).

TABLE 2:Drugs that resulted in ADEs in the study population.Drug namen (%)ACE inhibitors\*34 (33.3)Amiodarone13 (12.7)Acetylsalicylic acid9 (8.8)Hydrochlorothiazide7 (6.9)Spironolactone6 (5.9)Warfarin5 (4.9)Digoxin4 (3.9)Propranolol4 (3.9)Isosorbide4 (3.9)Amlodipine3 (2.9)Benznidazole3 (2.9)Carvedilol2 (2.0)Furosemide2 (2.0)Diazepam1 (1.0)Losartan1 (1.0)Methyldopa1 (1.0)Nifedipine1 (1.0)Sotalol1 (1.0)Ferrous sulfate1 (1.0)Total number of drugs (n=19)Total events (n=102)[^4]

The types of ADEs detected are presented in [Table 3](#t3){ref-type="table"}. The most frequent ADEs among the study population were cough (n=28; 8.8%) and hyperkalemia (n=3; 0.9%) for the ACE inhibitor; endocrine disorders (n=4; 1.3%) and respiratory disorders (n=3; 0.9%) for amiodarone; and bleeding (n=4; 1.3%) and epigastralgia (n=3; 0.9%) for acetylsalicylic acid.

TABLE 3:Frequency of drugs and the distribution of ADEs in the patient medical notes.DrugADRsFrequency, n (%)Total, n (%)**ACE inhibitor (Captopril + enalapril)**Cough28 (8.8)34 (10.6)Nausea /Gastric intolerance1 (0.3)Hypotension1 (0.3)Hyperkalemia2 (0.6)Presyncope1 (0.3)Dizziness1 (0.3)**Amiodarone**Endocrine disorders4 (1.3)13 (4.1)Dizziness1 (0.3)Cerebellar syndrome1 (0.3)Drowsiness and hypotension1 (0.3)Ophthalmic disorders2 (0.6)Hepatitis1 (0.3)Respiratory disorders3 (0.9)**Acetylsalicylic acid**Bleeding4 (1.3)9 (2.8)Epigastralgia3 (0.9)Urticaria2 (0.6)**Hydrochlorothiazide**Nausea and epigastric pain1 (0.3)7 (2.2)Hypokalemia1 (0.3)Hyponatremia1 (0.3)Renal disorders1 (0.3)Hypotension2 (0.6)Orthostatic hypotension1 (0.3)**Spironolactone**Hyperkalemia3 (0.9)6 (1.9)Gynecomastia2 (0.6)Hypotension1 (0.3)**Warfarin**Increased INR1 (0.3)5 (1.6)Bleeding1 (0.3)Hematuria1 (0.3)Dermatitis2 (0.6)**Digoxin**Gynecomastia1 (0.3)4 (1.3)Bradycardia1 (0.3)Weakness1 (0.3)Bigeminy1 (0.3)**Propranolol**Hypotension1 (0.3)4 (1.3)Intense bradycardia1 (0.3)Bronchospasm1 (0.3)Dizziness1 (0.3)**Isosorbide**Hypotension1 (0.3)4 (1.3)Severe headache1 (0.3)Headache with nitrate1 (0.3)Dysphagia and dizziness1 (0.3)**Amlodipine**MMII Edema1 (0.3)3 (0.9)Edema1 (0.3)Lower limb edema1 (0.3)**Benznidazole**Leukopenia1 (0.3)3 (0.9)Memory deficit1 (0.3)Amnesia and mental confusion1 (0.3)**Carvedilol**Bronchospasm1 (0.3)2 (0.6)Erectile dysfunction1 (0.3)**Furosemide**Paresthesia1 (0.3)2 (0.6)Hypotension1 (0.3)**Diazepam**Discouragement and daytime prostatitis1 (0.3)1 (0.3)**Losartan**Dizziness and drowsiness1 (0.3)1 (0.3)**Methyldopa**Postural hypotension1 (0.3)1 (0.3)**Nifedipine**Hypotension and redness on face1 (0.3)1 (0.3)**Sotalol**Bradycardia, dizziness, and sweating1 (0.3)1 (0.3)**Ferrous sulfate**Dizziness1 (0.3)1 (0.3)

The ACE inhibitor is frequently used to treat patients with chronic heart failure; however, some patients experience intolerance, mainly with captopril and enalapril, that may cause dry cough[@B8]. In the present study, 28 (8.8%) cases of cough were observed and classified as adverse reactions related to captopril use, a finding that is very similar to that of Hamad et al*.* [@B9] (5%). Although amiodarone is considered safe for the treatment of arrhythmias, it can cause thyroid dysfunction, which should be monitored at baseline and every 6 months during therapy[@B2] ^,^ [@B8] ^,^ [@B10]. Silva et al*.* [@B11] reported that 56.9% of patients had thyroid hormone alterations when treated with amiodarone. In the present study, amiodarone was discontinued due to hyperthyroidism in four (1.3% of events) patients. Thus, the low-frequency events could be consequence of the close and regular multidisciplinary follow-up conducted with our patients. Four minor gastrointestinal bleedings (1.3% of total ADRs) were also observed in our study, thereby leading to the discontinuation of ASA treatment. Such finding aligns with that of the literature as low-dose ASA was reported to be associated with the increased risk of any bleeding[@B12]. Herein, we also observed hyperkalemia due to spironolactone. Three hyperkalemia events (0.9%) occurred, a finding similar to Adorisio[@B8] and Botoni et al[@B13] who revealed that 4.8% of patients administered spironolactone presented hyperkalemia.

In the present study, the worsening of clinical status may have led to an increase in the number of drugs and consequently, the frequency of ADEs, as previously demonstrated[@B14]. However, although some studies have demonstrated that older patients are at a higher risk of developing ADEs, such finding was not confirmed herein. Instead, lower age was associated with more severe clinical presentations (B2, C and D; mean age of 54.1 years) in the present study. Patients with stages C/D had increased risk of ADEs compared to indeterminate patients. The increase in cardiac damage may lead to a greater risk of ADEs. For the severity classification, most ADEs were mild; this was followed by moderate reactions. Only five ADEs were identified as severe. The use of enalapril to replace captopril in patients requiring the use of ACE inhibitors may be better indicated for the prevention of ADEs and better adherence to treatment[@B2]. However, when cough is recurrent, the use of other ARBs, such as losartan, may serve as an alternative treatment[@B2]. Through this study, we could observe the frequency and type of ADEs caused by symptomatic or non-symptomatic pharmacological treatments in patients with chronic CD, as well as factors and drugs associated with these events. A close follow-up of these patients may thus reduce the frequency of ADEs. Recent clinical trials performed in this setting by our research group have confirmed this hypothesis in patients with heart failure induced by chronic CD[@B15].

In conclusion, the advanced stages of Chagas heart disease (C/D) and age have a significant association with the presence of ADEs. Furthermore, when cough was identified as the main frequently observed adverse event of the ACE inhibitors, losartan could be administered as an alternative to minimize this side effect.
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